Population PK parameters for pembrolizumab
| Parameters | Nonmem | Bootstrap | ||||||
| Estimate | RSE (%) | 95% CI (lower) | 95% CI (upper) | Shrink. (%) | Median | 95% CI (lower) | 95% CI (upper) | |
| Pop parameters | ||||||||
| CL (L/day) | 0.257 | 3.3 | 0.24 | 0.26 | – | 0.256 | 0.24 | 0.27 |
| V (L) | 6.8 | 8.6 | 5.66 | 7.95 | – | 6.9 | 5.31 | 8.71 |
| Covariates | ||||||||
| BSA~CL | 1.46 | 24 | 0.78 | 2.14 | – | 1.50 | 0.80 | 2.20 |
| Albumin~CL | −1.43 | 27 | −2.19 | −0.67 | – | −1.40 | −2.31 | −0.75 |
| UCC~CL | 1.29 | 11 | 1.02 | 1.56 | – | 1.28 | 1.02 | 1.62 |
| Meso~V | 0.58 | 23 | 0.32 | 0.84 | – | 0.57 | 0.32 | 0.9 |
| LDH~V | 0.34 | 21 | 0.20 | 0.48 | – | 0.33 | 0.14 | 0.52 |
| Variability | ||||||||
| IIV CL (%) | 31 | 8.5 | 25 | 36 | 8 | 30 | 24 | 35 |
| IIV V (%) | 29 | 11 | 22 | 35 | 30 | 28 | 21 | 36 |
| Residual error | 0.17 | 7 | 0.14 | 0.19 | 14 | 0.16 | 0.14 | 0.19 |
Showing the population parameters estimates, covariate effects and inter-individualvariability of the final population PK model.
BSA, body surface area; CL, clearance; CV%, percentage coefficient of variation; IIV, inter-individual variability; LDH, lactate dehydrogenase; Meso, malignant pleural mesothelioma; PK, pharmacokinetic; RSE, relative SE; UCC, urothelial cell carcinoma; V, volume of distribution.